Jamjoom Pharma presents a strong investment case supported by consistent financial performance, a scalable operating platform, and disciplined execution of its growth strategy.
Revenue reached 1.5 billion in 2025, reflecting a robust 13.8% YoY increase and aligning with management’s revenue guidance of 12–15% CAGR.
The Company has a strong track record of growth, outperforming its peers in the Saudi Arabia market with a 20% CAGR from 2021 to 2025.
Jamjoom Pharma continues to delivery high profitability, with a net profit margin of 30.9% (+3.9 percentage points compared to 2024) and an EBITDA margin of 35.5% (+2.3 percentage points increase). Net profit growth consistently outpaces revenue growth, driven by operating leverage and the portfolio mix.
Dividend payout of 50–60% of net profit, paid semi-annually, reflects the Company’s focus on providing high shareholder returns.
Robust zero-debt balance sheet, with expansion funded through retained earnings, making Jamjoom Pharma self-sufficient and financially stable under any market conditions.
6.3% pharmaceutical market share in the Saudi Arabia retail market
#1 in the ophthalmology TA
#2 in the dermatology TA
ROA 22.6% (+2.5 p. p. compared to 2024)
ROE 27.0% (+3.1 p. p. compared to 2024)
Jamjoom Pharma holds a dominant market share in Saudi Arabia across key therapeutic areas such as ophthalmology and dermatology.
The Company expanded its footprint across 30+ countries with significant growth in key markets like Iraq, Egypt, and the Gulf.
EBITDA margins are the highest among Saudi-listed pharma peers, and among the strongest regionally.
Established partnerships with healthcare providers, medical societies, and government agencies support regional market leadership.
The Company launched six new brands in 2025, including advancements, and is currently working on 57 products in different stages of the development pipeline.
Expansion into consumer health and regionally prevalent disease therapy allows us to leverage high demand. As just one example, our anti-diabetic portfolio recorded a spectacular 40% revenue growth in 2025.
57 products in the development pipeline
Fully operational Jeddah Sterile Facility enables production of high-demand ophthalmology products, supporting the ophthalmology market leadership in Saudi Arabia.
Expansion of manufacturing capacity in Egypt supports regional self-sufficiency and allows addressing two-thirds of the local market demand.
AI-driven technologies enhance operational efficiency and scalability.
Production shifting strategically across facilities optimises capacity utilisation and enables upgrades.
Jamjoom Pharma is a key contributor to Saudi Vision 2030 goals, promoting pharmaceutical localisation and job creation.
The Company is committed to sustainable practices, including energy-efficient production and reduced environmental impact.
Two new agreements were reached in 2025 to localise and expand Saudi Arabia’s biopharmaceutical sector.
Continuous expansion of institutional sales strengthens national healthcare supply security.
16 strategic Business Development agreements with global partners
Jamjoom Pharma is led by an experienced management team with a proven track record of delivering results.
A strong corporate governance framework ensures transparency and accountability.
A diverse Board of Directors with a broad range of expertise and vision is well-positioned to lead the Company forward.
Jamjoom Pharma Academy supports internal capability building.
>40 % of the Board members are independent directors
The Company leverages high-growth opportunities in underserved regions, supported by tailored market-entry strategies.
Strategic focus on expanding presence in Francophone Africa and other emerging markets creates additional potential for growth.
Inorganic growth is expected to contribute meaningfully from 2026 onward.
+15.3 % sales increase in the Kingdom of Saudi Arabia in 2025
+15.1 % growth in North Africa and other export markets
Outpacing total revenue growth of +13.8%
